DrugPatentWatch Database Preview
Belcher Pharms Company Profile
What is the competitive landscape for BELCHER PHARMS, and when can generic versions of BELCHER PHARMS drugs launch?
BELCHER PHARMS has nine approved drugs.
There are three US patents protecting BELCHER PHARMS drugs.
Summary for Belcher Pharms
| US Patents: | 3 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 9 |
Drugs and US Patents for Belcher Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belcher Pharms Llc | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 206651-001 | Nov 30, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Belcher Pharms Llc | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 206651-003 | Nov 30, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Belcher Pharms Llc | EPINEPHRINE | epinephrine | SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | 205029-001 | Jul 29, 2014 | RX | Yes | Yes | 9,283,197 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Belcher Pharms Llc | SODIUM POLYSTYRENE SULFONATE | sodium polystyrene sulfonate | POWDER;ORAL, RECTAL | 205727-001 | Feb 23, 2016 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Belcher Pharms Llc | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 206651-002 | Nov 30, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
